Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocytosis 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1

Interventions

Peripheral Blood Stem Cell Transplantation 3fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Pentetic Acid 2Methotrexate 2Decitabine 2Cyclosporins 2Cyclosporine 2Busulfan 2spartalizumab 1siltuximab 1sabatolimab 1ruxolitinib 1pelcitoclax 1merphos 1ethanolamine oleate 1durvalumab 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Therapeutics 1Sulfamethoxazole 1Sodium Chloride 1Saline Solution, Hypertonic 1Saline Solution 1Psychiatric Rehabilitation 1Pentostatin 1Ondansetron 1NIS-793 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Primary Myelofibrosis × pelcitoclax × Clear all
NCT04354727 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Ascentage Pharma Group Inc.

Phase 1/2 Withdrawn
Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡